• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
OSL
Click for more information
0.00% 0.7¢

ONCOSIL MEDICAL LTD - Announcements

Market Cap $49.19M  ! watchlist Created with Sketch. Add to my watchlist

OncoSil Medical Ltd is an Australia-based medical device company focused on localized... OncoSil Medical Ltd is an Australia-based medical device company focused on localized treatments for patients with unresectable locally advanced pancreatic cancer (LAPC). The Company is focused on the development and commercialization of its lead product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The Company has developed a cancer treatment device, the OncoSil brachytherapy device, which is a critical component of a brachytherapy treatment for locally advanced unresectable pancreatic cancer. The OncoSil device delivers a targeted intratumoral placement of Phosphorous-32 (32P) in the treatment of locally advanced unresectable pancreatic cancer. The OncoSil device has received a device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
OSL CE Marking UpdatePRICE SENSITIVE25/03/19
OSL Half Yearly Report and AccountsPRICE SENSITIVE20/02/19
OSL Appendix 4C - quarterlyPRICE SENSITIVE31/01/19
OSL Initial Director's Interest Notice11/12/18
OSL Director Appointment/Resignation10/12/18
OSL Loan Share Vesting Conditions Met02/11/18
OSL Appendix 3B31/10/18
OSL Results of Annual General Meeting 2018 - Amended30/10/18
OSL Results of Annual General Meeting 201830/10/18
OSL 2018 AGM CEO Presentation30/10/18
OSL Appendix 4C - quarterlyPRICE SENSITIVE29/10/18
OSL PanCo Study Interim AnalysisPRICE SENSITIVE25/10/18
OSL 2018 Notice of General Meeting & Proxy Form28/09/18
OSL 2018 Annual Report28/09/18
OSL 2018 Appendix 4G and Corporate Governance Statement28/09/18
OSL R&D Refund - 2018 Financial YearPRICE SENSITIVE24/09/18
OSL IQVIA appointed EU Market Access and Reimbursement AdvisorPRICE SENSITIVE30/08/18
OSL Preliminary Final ReportPRICE SENSITIVE22/08/18
OSL Oncosil Company Update Presentation26/07/18
OSL Appendix 4C & Quarterly UpdatePRICE SENSITIVE25/07/18
OSL OSL to present at Monsoon Communications Investor Event05/07/18
OSL OncoSil Company Update Presentation04/06/18
OSL Response to Price QueryPRICE SENSITIVE31/05/18
OSL Appendix 3Y - Dr Roger Aston18/05/18
OSL Appendix 3Y - Dr Chris Roberts18/05/18
OSL Appendix 3Y - Dr Martin Cross18/05/18
OSL Appendix 3B17/05/18
OSL Results of Extraordinary General Meeting 201814/05/18
OSL Oncosil submits Clinical Study Report to Notified BodyPRICE SENSITIVE14/05/18
OSL OSL to present at Finance News Network Investor Session02/05/18
OSL Appendix 3Y - Dr Martin Cross Share Purchase Plan26/04/18
OSL Appendix 3Y - Daniel Kenny Share Purchase Plan26/04/18
OSL Appendix 3Y - Dr Chris Roberts Share Purchase Plan26/04/18
OSL Appendix 4C & Quarterly UpdatePRICE SENSITIVE26/04/18
OSL Appendix 3B - Share Purchase Plan20/04/18
OSL ASIC Form 48420/04/18
OSL OncoSil Medical raises $4.0m from Share Purchase Plan19/04/18
OSL EGM Notice of Meeting & Proxy Form13/04/18
OSL Oncosil Medical Share Purchase Plan Closing Date Reminder11/04/18
OSL Oncosil Medical presents at Proactive Investors CEO Sessions09/04/18
OSL Clinical Programme UpdatePRICE SENSITIVE04/04/18
OSL Change in substantial holding03/04/18
OSL CEO Interview - Clinical data update and outlook video03/04/18
OSL Ceasing to be a substantial holder for OSL28/03/18
OSL Oncosil Medical Share Purchase PlanPRICE SENSITIVE28/03/18
OSL Cleansing Statement & Appendix 3B28/03/18
OSL Successful Completion of Capital RaisingPRICE SENSITIVE22/03/18
OSL Presentation-Surgical Resection Outcomes and Capital RaisingPRICE SENSITIVE21/03/18
OSL Surgical Resection Outcomes and Capital RaisingPRICE SENSITIVE21/03/18
OSL Trading HaltPRICE SENSITIVE21/03/18
OSL OncoSil Company Update Presentation08/03/18
OSL Appendix 3B02/03/18
OSL Positive Early Study Results ContinuePRICE SENSITIVE28/02/18
OSL Appendix 4D & Half Yearly Report and AccountsPRICE SENSITIVE21/02/18
OSL Change in substantial holding08/02/18
OSL First Subject Recruited in the United StatesPRICE SENSITIVE08/02/18
OSL Response to ASX Appendix 4C QueryPRICE SENSITIVE08/02/18
OSL Change of Director's Interest Notice - Appendix 3Y30/01/18
OSL Change of Director's Interest Notice - Appendix 3Y30/01/18
OSL Final share buy-back notice - Appendix 3F30/01/18
OSL Appendix 4C & Quarterly UpdatePRICE SENSITIVE29/01/18
OSL Additional Receipt of $0.6m R&D Tax Incentive RefundPRICE SENSITIVE16/01/18
OSL Appendix 3C - Employee Loan Share Buy BackPRICE SENSITIVE11/01/18
OSL 20th Patient implanted with OncoSil device10/01/18
OSL Progress Update on Global Pancreatic Cancer Clinical StudyPRICE SENSITIVE21/12/17
OSL Loan Share Vesting Conditions Met23/11/17
OSL Appendix 4C & Quarterly UpdatePRICE SENSITIVE31/10/17
OSL Change in substantial holding26/10/17
OSL Results of Annual General Meeting 201725/10/17
OSL Australia Biotech Invest 2017 Presentation24/10/17
OSL Positive Early Study Results Presented at EANM CongressPRICE SENSITIVE23/10/17
OSL Progress Update on Global Pancreatic Cancer Clinical StudyPRICE SENSITIVE16/10/17
OSL R&D RefundPRICE SENSITIVE25/09/17
OSL Progress update on Global Pancreatic Cancer Clinical StudyPRICE SENSITIVE22/09/17
OSL 2017 Notice of Meeting and Proxy Form21/09/17
OSL 2017 Oncosil Annual Report21/09/17
OSL 2017 Appendix 4G and Corporate Governance Statement21/09/17
OSL Appendix 4E - Preliminary Final Report 30 June 2017PRICE SENSITIVE24/08/17
OSL First UK subject recruitedPRICE SENSITIVE22/08/17
OSL CE Mark & Quarterly Activity UpdatePRICE SENSITIVE31/07/17
OSL Resignation of Company Secretary25/07/17
OSL Change in substantial shareholder17/05/17
OSL Cleansing Notice & Appendix 3B12/05/17
OSL Second subject recruited at Monash Health MelbournePRICE SENSITIVE11/05/17
OSL Dr Roger Aston, Non-Executive Director04/05/17
OSL Appointment of Dr Chris Roberts AO as Chairman03/05/17
OSL Appendix 4C and Quarterly updatePRICE SENSITIVE27/04/17
OSL First OncoSil Device Implantation procedure completedPRICE SENSITIVE26/04/17
OSL Specialised Therapeutics Australia supporting OncoSil studyPRICE SENSITIVE20/04/17
OSL US IRB Approval, MD Anderson Cancer CentrePRICE SENSITIVE19/04/17
OSL Loan Share Vesting Conditions Met10/04/17
OSL Notice of change of substantial holder10/04/17
OSL UK Central Ethics ApprovalPRICE SENSITIVE04/04/17
OSL First subject recruitedPRICE SENSITIVE28/03/17
OSL Appendix 3X - Initial Directors Interest Notice28/02/17
OSL Dr Martin Cross appointed Non-Executive Director28/02/17
OSL Appendix 4D & Half Year AccountsPRICE SENSITIVE23/02/17
OSL MHRA Approval to commence study in UKPRICE SENSITIVE13/02/17
OSL CE Mark UpdatePRICE SENSITIVE08/02/17
OSL Ethics Approval for OncoPac Clinical StudyPRICE SENSITIVE02/02/17
OSL CE Marking Update
25/03/19PRICE SENSITIVE
OSL Half Yearly Report and Accounts
20/02/19PRICE SENSITIVE
OSL Appendix 4C - quarterly
31/01/19PRICE SENSITIVE
OSL Initial Director's Interest Notice
11/12/18
OSL Director Appointment/Resignation
10/12/18
OSL Loan Share Vesting Conditions Met
02/11/18
OSL Appendix 3B
31/10/18
OSL Results of Annual General Meeting 2018 - Amended
30/10/18
OSL Results of Annual General Meeting 2018
30/10/18
OSL 2018 AGM CEO Presentation
30/10/18
OSL Appendix 4C - quarterly
29/10/18PRICE SENSITIVE
OSL PanCo Study Interim Analysis
25/10/18PRICE SENSITIVE
OSL 2018 Notice of General Meeting & Proxy Form
28/09/18
OSL 2018 Annual Report
28/09/18
OSL 2018 Appendix 4G and Corporate Governance Statement
28/09/18
OSL R&D Refund - 2018 Financial Year
24/09/18PRICE SENSITIVE
OSL IQVIA appointed EU Market Access and Reimbursement Advisor
30/08/18PRICE SENSITIVE
OSL Preliminary Final Report
22/08/18PRICE SENSITIVE
OSL Oncosil Company Update Presentation
26/07/18
OSL Appendix 4C & Quarterly Update
25/07/18PRICE SENSITIVE
OSL OSL to present at Monsoon Communications Investor Event
05/07/18
OSL OncoSil Company Update Presentation
04/06/18
OSL Response to Price Query
31/05/18PRICE SENSITIVE
OSL Appendix 3Y - Dr Roger Aston
18/05/18
OSL Appendix 3Y - Dr Chris Roberts
18/05/18
OSL Appendix 3Y - Dr Martin Cross
18/05/18
OSL Appendix 3B
17/05/18
OSL Results of Extraordinary General Meeting 2018
14/05/18
OSL Oncosil submits Clinical Study Report to Notified Body
14/05/18PRICE SENSITIVE
OSL OSL to present at Finance News Network Investor Session
02/05/18
OSL Appendix 3Y - Dr Martin Cross Share Purchase Plan
26/04/18
OSL Appendix 3Y - Daniel Kenny Share Purchase Plan
26/04/18
OSL Appendix 3Y - Dr Chris Roberts Share Purchase Plan
26/04/18
OSL Appendix 4C & Quarterly Update
26/04/18PRICE SENSITIVE
OSL Appendix 3B - Share Purchase Plan
20/04/18
OSL ASIC Form 484
20/04/18
OSL OncoSil Medical raises $4.0m from Share Purchase Plan
19/04/18
OSL EGM Notice of Meeting & Proxy Form
13/04/18
OSL Oncosil Medical Share Purchase Plan Closing Date Reminder
11/04/18
OSL Oncosil Medical presents at Proactive Investors CEO Sessions
09/04/18
OSL Clinical Programme Update
04/04/18PRICE SENSITIVE
OSL Change in substantial holding
03/04/18
OSL CEO Interview - Clinical data update and outlook video
03/04/18
OSL Ceasing to be a substantial holder for OSL
28/03/18
OSL Oncosil Medical Share Purchase Plan
28/03/18PRICE SENSITIVE
OSL Cleansing Statement & Appendix 3B
28/03/18
OSL Successful Completion of Capital Raising
22/03/18PRICE SENSITIVE
OSL Presentation-Surgical Resection Outcomes and Capital Raising
21/03/18PRICE SENSITIVE
OSL Surgical Resection Outcomes and Capital Raising
21/03/18PRICE SENSITIVE
OSL Trading Halt
21/03/18PRICE SENSITIVE
OSL OncoSil Company Update Presentation
08/03/18
OSL Appendix 3B
02/03/18
OSL Positive Early Study Results Continue
28/02/18PRICE SENSITIVE
OSL Appendix 4D & Half Yearly Report and Accounts
21/02/18PRICE SENSITIVE
OSL Change in substantial holding
08/02/18
OSL First Subject Recruited in the United States
08/02/18PRICE SENSITIVE
OSL Response to ASX Appendix 4C Query
08/02/18PRICE SENSITIVE
OSL Change of Director's Interest Notice - Appendix 3Y
30/01/18
OSL Change of Director's Interest Notice - Appendix 3Y
30/01/18
OSL Final share buy-back notice - Appendix 3F
30/01/18
OSL Appendix 4C & Quarterly Update
29/01/18PRICE SENSITIVE
OSL Additional Receipt of $0.6m R&D Tax Incentive Refund
16/01/18PRICE SENSITIVE
OSL Appendix 3C - Employee Loan Share Buy Back
11/01/18PRICE SENSITIVE
OSL 20th Patient implanted with OncoSil device
10/01/18
OSL Progress Update on Global Pancreatic Cancer Clinical Study
21/12/17PRICE SENSITIVE
OSL Loan Share Vesting Conditions Met
23/11/17
OSL Appendix 4C & Quarterly Update
31/10/17PRICE SENSITIVE
OSL Change in substantial holding
26/10/17
OSL Results of Annual General Meeting 2017
25/10/17
OSL Australia Biotech Invest 2017 Presentation
24/10/17
OSL Positive Early Study Results Presented at EANM Congress
23/10/17PRICE SENSITIVE
OSL Progress Update on Global Pancreatic Cancer Clinical Study
16/10/17PRICE SENSITIVE
OSL R&D Refund
25/09/17PRICE SENSITIVE
OSL Progress update on Global Pancreatic Cancer Clinical Study
22/09/17PRICE SENSITIVE
OSL 2017 Notice of Meeting and Proxy Form
21/09/17
OSL 2017 Oncosil Annual Report
21/09/17
OSL 2017 Appendix 4G and Corporate Governance Statement
21/09/17
OSL Appendix 4E - Preliminary Final Report 30 June 2017
24/08/17PRICE SENSITIVE
OSL First UK subject recruited
22/08/17PRICE SENSITIVE
OSL CE Mark & Quarterly Activity Update
31/07/17PRICE SENSITIVE
OSL Resignation of Company Secretary
25/07/17
OSL Change in substantial shareholder
17/05/17
OSL Cleansing Notice & Appendix 3B
12/05/17
OSL Second subject recruited at Monash Health Melbourne
11/05/17PRICE SENSITIVE
OSL Dr Roger Aston, Non-Executive Director
04/05/17
OSL Appointment of Dr Chris Roberts AO as Chairman
03/05/17
OSL Appendix 4C and Quarterly update
27/04/17PRICE SENSITIVE
OSL First OncoSil Device Implantation procedure completed
26/04/17PRICE SENSITIVE
OSL Specialised Therapeutics Australia supporting OncoSil study
20/04/17PRICE SENSITIVE
OSL US IRB Approval, MD Anderson Cancer Centre
19/04/17PRICE SENSITIVE
OSL Loan Share Vesting Conditions Met
10/04/17
OSL Notice of change of substantial holder
10/04/17
OSL UK Central Ethics Approval
04/04/17PRICE SENSITIVE
OSL First subject recruited
28/03/17PRICE SENSITIVE
OSL Appendix 3X - Initial Directors Interest Notice
28/02/17
OSL Dr Martin Cross appointed Non-Executive Director
28/02/17
OSL Appendix 4D & Half Year Accounts
23/02/17PRICE SENSITIVE
OSL MHRA Approval to commence study in UK
13/02/17PRICE SENSITIVE
OSL CE Mark Update
08/02/17PRICE SENSITIVE
OSL Ethics Approval for OncoPac Clinical Study
02/02/17PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
0.7¢ 		Change
0.000(0.00%) 		Mkt cap ! $49.19M
Open High Low Value Volume
0.7¢ 0.8¢ 0.7¢ $22.19K 3.074M

Buyers (Bids)

No. Vol. Price($)
74 32326939 0.7¢
 

Sellers (Offers)

Price($) Vol. No.
0.8¢ 3361400 6
View Market Depth
Last trade - 16.10pm 21/11/2024 (20 minute delay) ?
Last
0.8¢ 		  Change
0.000 ( 7.14 %)
Open High Low Volume
0.8¢ 0.8¢ 0.7¢ 1920007
Last updated 15.56pm 21/11/2024 ?
OSL (ASX) Chart

Top Stories

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
Alcidion inks deal with Vic health provider Peninsula for use of Miya Precision tech Alcidion Group Ltd has signed a contract worth $3.7M to enable use of its Miya Precision platform by users of Peninsula Health entities
Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.